Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
4.780
0.00 (0.00%)
At close: Mar 11, 2026, 4:00 PM EDT
4.734
-0.046 (-0.97%)
After-hours: Mar 11, 2026, 7:51 PM EDT

Atossa Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
14.4213.514.0412.6111.318
Research & Development
18.4314.1217.3315.089.216.61
Other Operating Expenses
--1.71-2.99---
Total Operating Expenses
32.8625.9128.3927.6920.5214.61
Operating Income
-32.86-27.62-31.38-27.69-20.52-14.61
Interest Income
2.774.054.340.880.01-
Other Non-Operating Income (Expense)
-0.1-0.22-0.07-0.15-0.09-3.22
Total Non-Operating Income (Expense)
2.683.834.270.73-0.09-3.22
Pretax Income
-30.18-25.5-30.09-26.96-20.61-17.83
Net Income
-30.18-25.5-30.09-26.96-20.61-17.83
Net Income Attributable to Preferred Dividends
-----4.5
Net Income to Common
-30.18-25.5-30.09-26.96-20.61-17.83
Shares Outstanding (Basic)
988881
Shares Outstanding (Diluted)
988881
Shares Change (YoY)
2.39%-0.18%-0.43%8.27%934.13%33.09%
EPS (Basic)
-3.60-3.00-3.60-3.15-2.70-29.55
EPS (Diluted)
-3.60-3.00-3.60-3.15-2.70-29.55
Free Cash Flow
-26.3-21.05-20.96-20.79-16.48-11.58
Free Cash Flow Per Share
-3.07-2.51-2.49-2.46-2.11-15.36
EBITDA
-32.84-27.6-31.35-27.68-20.5-14.56
EBIT
-32.86-27.62-31.38-27.69-20.52-14.61
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q